Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029)

PHASE3CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

August 28, 2014

Primary Completion Date

July 6, 2015

Study Completion Date

July 6, 2015

Conditions
Pneumococcal Infections
Interventions
BIOLOGICAL

Prevnar 13™

Pneumococcal vaccine containing serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. Injections are to be administered into the deltoid muscle of the upper arm.

BIOLOGICAL

Pneumovax™ 23

Pneumococcal vaccine containing serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. Injections are to be administered into the deltoid muscle of the upper arm.

BIOLOGICAL

Placebo

Injections are to be administered into the deltoid muscle of the upper arm.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02225587 - Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029) | Biotech Hunter | Biotech Hunter